Letter to FDA CDER Regarding Patent Matter

USPTO transmitted an inter-agency letter to FDA CDER on April 9, 2025, filed under docket FDA-2026-E-3811-0001. The correspondence is available as an attachment but the specific content is not visible in the document metadata.

Affected parties, particularly pharmaceutical manufacturers and patent holders, should monitor this docket for additional filings that may clarify the nature and implications of this USPTO-FDA coordination. Inter-agency communications between USPTO and FDA CDER typically involve patent listing requirements, Orange Book matters, or drug approval process coordination.